AngioDynamics (ANGO)
AngioDynamics SG&A Expense: 20.24M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
ANGO SG&A Expense Rankings
| Overall | 52nd percentile | 2000 of 4190 |
| Sector | 34th percentile | 319 of 485 in Healthcare |
| Industry | 40th percentile | 37 of 62 in Medical Instruments & Supplies |
ANGO SG&A Expense Range, Past 5 Years
| Minimum | 14.68M | Aug 2007 |
| Maximum | 20.79M | May 2009 |
| Average | 18.41M |
About SG&A Expense
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
The details of how SG&A expenses are calculated vary widely from company to company, so YCharts recommends looking at the annual report (10-k) an investor is interested in dissecting this number further.
Learn More
You may also be interested in these ANGO related companies
ANGO News
AngioDynamics Completes Acquisition of Navilyst Medical http://stks.co/3vuI $ANGO
about 5 days ago by evcgroup
about 5 days ago by evcgroup
AngioDynamics Shareholders Approve Share Issuance for Navilyst Medical Acquisition
http://stks.co/3qGr $ANGO
about 12 days ago by evcgroup
about 12 days ago by evcgroup
AngioDynamics Shareholders Approve Share Issuance for Navilyst Medical Acquisition
May 15, 5:04PM GlobeNewswire
May 15, 5:04PM GlobeNewswire
RT @MedDevice ABC on Dr. Cunningham of @VeinClinics on the VenaCure 1470 for varicose veins bit.ly/VeinClinicsofAmericaBrentwood $ANGO
about 20 days ago by evcgroup
about 20 days ago by evcgroup
AngioDynamics' CEO Discusses Q3 2012 Results - Earnings Call Transcript
Apr 04, 8:50PM Seeking Alpha
Apr 04, 8:50PM Seeking Alpha
Listen to $ANGO Q3 2012 earnings call - live at 04:30 PM, ondemand after - http://stks.co/3E55
about 53 days ago by earningscast
about 53 days ago by earningscast
NanoKnife® System Clinical Experience Featured at Society of Surgical Oncology Conference
Apr 02, 6:30AM Business Wire
Apr 02, 6:30AM Business Wire
Canaccord Genuity Maintains a 'Buy' on AngioDynamics (ANGO); Q3 Preview
Mar 30, 8:40AM Street Insider
Mar 30, 8:40AM Street Insider
AngioDynamics Establishes Strategic Relationship with Microsulis Medical Ltd.
Mar 26, 6:40AM Benzinga
Mar 26, 6:40AM Benzinga
AngioDynamics (ANGO) Invests, Enters Distribution Agreement with Microsulis Medical
Mar 26, 6:36AM Street Insider
Mar 26, 6:36AM Street Insider
AngioDynamics to Report Fiscal 2012 Third Quarter Financial Results and Hold Conference Call on April 4, 2012
Mar 21, 6:30AM GlobeNewswire
Mar 21, 6:30AM GlobeNewswire
AngioDynamics Receives FDA Clearance for NeverTouch Direct Procedure Kit to be Used With VenaCure EVLT System
http://stks.co/2OQd $ANGO
about 103 days ago by evcgroup
about 103 days ago by evcgroup
AngioDynamics Launches DuraFlow 2 Chronic Hemodialysis Catheter http://stks.co/2InF $ANGO
about 109 days ago by evcgroup
about 109 days ago by evcgroup
$ANGO 200 Day SMA Cross - Price crossed below 200 day SMA (14.4842). Confirmed by volume.
about 117 days ago by TradeIdeasQuant
about 117 days ago by TradeIdeasQuant
$ANGO Q3 adj-EPS from 9-11c to 7-9c, Q4 from 11-13c to 10-12c, FY12 from 41-45c to 38-42c
about 124 days ago by Street_Insider
about 124 days ago by Street_Insider
Listen to $ANGO Q2 2012 earnings call - live at 04:30 PM, ondemand after - http://stks.co/1nIm
about 143 days ago by earningscast
about 143 days ago by earningscast
$ANGO Reports Q2 EPS $0.09 vs $0.12 Est; Revenues $58.10M vs $56.26M Est
about 143 days ago by Benzinga
about 143 days ago by Benzinga
AngioDynamics' new VenaCure 1470 in Houston http://stks.co/1PWW $ANGO
about 173 days ago by evcgroup
about 173 days ago by evcgroup
Listen to $ANGO at piper jaffray health care conference - live at 03:00 PM, ondemand after - http://stks.co/1KNG
about 179 days ago by earningscast
about 179 days ago by earningscast
AngioDynamics Expands Senior Leadership Team $ANGO http://stks.co/11Gy
about 201 days ago by evcgroup
about 201 days ago by evcgroup
RT @EVCGroup RT @MedDevice Here's where varicose vein treatment is today, a solid summary in Vascular Disease Management goo.gl/j3Vk1 $ANGO
about 205 days ago by evcgroup
about 205 days ago by evcgroup
$ANGO Reports Q1 EPS $0.08 vs $0.08 Est; Revenue $54.4M vs $53.86M Est; Announces Stock Repurchase Authorization of up to $20M
about 234 days ago by Benzinga
about 234 days ago by Benzinga
AngioDynamics $ANGO shares falling as FDA issues warning letter over NY plant inspection
about 271 days ago by Street_Insider
about 271 days ago by Street_Insider
After falling about 3% before the Nasdaq could halt, shares of $ANGO have bounced upon resumption, now down about 1.2% from today's close.
about 488 days ago by Street_Insider
about 488 days ago by Street_Insider
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| ANGO | 12.20 | -0.13 | -1.05% | 306.46M |
| ANGN | 5.85 | +0.20 | +3.54% | 22.93M |
| ANF | 36.23 | +0.94 | +2.66% | 3.069B |
| ANEN | 19.05 | +0.06 | +0.32% | 283.65M |
| ASPS | 57.98 | -1.04 | -1.76% | 1.352B |
| ASP | 11.61 | -0.05 | -0.46% | |
| ASNA | 18.90 | -0.02 | -0.11% | 2.896B |
| ASML | 46.00 | -0.22 | -0.48% | 19.03B |
| ASMI | 35.28 | -0.28 | -0.79% | 1.954B |
| ASM | 1.24 | -0.01 | -0.72% | 25.52M |
